Audentes Therapeutics Inc (NASDAQ:BOLD) saw an uptick in trading volume on Friday . 1,448,627 shares changed hands during mid-day trading, an increase of 163% from the previous session’s volume of 550,612 shares.The stock last traded at $38.10 and had previously closed at $38.07.
Several brokerages recently weighed in on BOLD. Svb Leerink lifted their price target on Audentes Therapeutics from $37.00 to $48.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. ValuEngine lowered Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 18th. Piper Jaffray Companies lifted their price target on Audentes Therapeutics from $45.00 to $55.00 and gave the company a “positive” rating in a research note on Monday, April 8th. Wedbush lifted their price target on Audentes Therapeutics from $52.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, April 9th. Finally, BidaskClub upgraded Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 17th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $39.92.
The firm has a market capitalization of $1.69 billion, a PE ratio of -11.21 and a beta of 1.85.
In related news, VP Suyash Prasad sold 10,000 shares of Audentes Therapeutics stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $30.06, for a total value of $300,600.00. Following the sale, the vice president now directly owns 28,236 shares in the company, valued at approximately $848,774.16. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Matthew R. Patterson sold 21,000 shares of Audentes Therapeutics stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $30.00, for a total value of $630,000.00. Following the completion of the sale, the chief executive officer now owns 135,700 shares in the company, valued at $4,071,000. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,000 shares of company stock worth $2,020,400. 5.30% of the stock is currently owned by insiders.
A number of hedge funds have recently bought and sold shares of BOLD. Great Point Partners LLC acquired a new stake in Audentes Therapeutics in the 4th quarter worth about $35,346,000. Partner Fund Management L.P. boosted its holdings in shares of Audentes Therapeutics by 94.4% during the 4th quarter. Partner Fund Management L.P. now owns 3,021,259 shares of the biotechnology company’s stock worth $64,413,000 after purchasing an additional 1,467,120 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its holdings in shares of Audentes Therapeutics by 913.5% during the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 1,619,831 shares of the biotechnology company’s stock worth $63,206,000 after purchasing an additional 1,459,999 shares during the last quarter. BB Biotech AG acquired a new position in shares of Audentes Therapeutics during the 4th quarter worth approximately $16,404,000. Finally, Millennium Management LLC acquired a new position in shares of Audentes Therapeutics during the 4th quarter worth approximately $12,600,000. Institutional investors own 97.95% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Audentes Therapeutics (BOLD) Sees Unusually-High Trading Volume” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/4353207/audentes-therapeutics-bold-sees-unusually-high-trading-volume.html.
Audentes Therapeutics Company Profile (NASDAQ:BOLD)
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Story: What is the LIBOR?
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.